{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-021414","form_type":"8-K","ticker":"LMAT","cik":"0001158895","company_name":"LEMAITRE VASCULAR INC","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.254744+00:00","generated_at":"2026-06-12T17:00:35.819046+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LeMaitre Q2 sales up 19% to $50.1M; EPS $0.36 (+127%); FY23 guidance raised; $0.14 dividend","bullets":["Sales $50.1M, +19% (+16% organic) vs Q2 2022; operating income $9.5M (+63%).","Net income $8.1M (+130%), diluted EPS $0.36 (+127%); adjusted EPS +25%.","Gross margin 64.0% (down from 66.0%); EMEA +26%, APAC +21%, Americas +16%.","FY23 guidance: sales $193M–$197.8M (+21%/+18% organic), EPS $1.23–$1.34 (ex-special $1.25–$1.35).","Quarterly dividend $0.14/share, payable Aug 31, record Aug 17; $25M buyback authorized."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-021414","json":"https://secwatch.observer/filing/0001437749-23-021414.json","markdown":"https://secwatch.observer/filing/0001437749-23-021414.md","text":"https://secwatch.observer/filing/0001437749-23-021414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923021414/0001437749-23-021414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923021414/lmat20230801_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T17:00:35.819046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49acc2c474129d7c4e6c1586197bf922b1bbc6f5","claim":"LEMAITRE VASCULAR INC reported the quarter ended June 30, 2023 results: revenue $50.1mm, net income $8.1mm, EPS $0.36. Guidance initiated.","evidence_excerpt":"of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q2 2023 Financial Results ● Sales $50.1mm, +19% (+16% organic) vs. Q2 2022 ● Op. income $9.5mm, +63% (+8% adjusted) ● Op. margin 19% ● Net income $8.1mm, +130% (+27% adjusted) ● Earnings per diluted share $0.36, +127%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923021414/0001437749-23-021414-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$50.1mm"},{"label":"Net income","value":"$8.1mm"},{"label":"EPS","value":"$0.36"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}